Navigation Links
Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm
Date:2/20/2009

BELGIUM, Wis., Feb. 20 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), a global health company that develops biotechnology based solutions for positive, long term benefit to the agricultural and consumer markets, announced today that it has closed on the acquisition of Modular Process Constructors LLC (MPC).

Mach One acquired 100% of the LLC interests of MPC for $500,000 of Series B convertible preferred stock at a conversion price of $0.50 cents per share. The purchase price was funded out of available authorized shares.

Monte B. Tobin, Chairman and Chief Executive Officer of Mach One, said, "This acquisition not only brings us the needed expertise to facilitate expansion of the animal division of our business model, it will be accretive to our revenues for 2009 as MPC obtains additional world class customers in the biopharmaceutical industry."

About Mach One Corporation

Mach One Corporation (www.machonecorp.com) is a global health company that provides biotechnology based solutions to help address one of the world's most pressing and costly needs--positive, long-term health and longevity benefits for disease-threatened animals of large commercial operations. Mach One provides broad spectrum immunoglobulin and nutraceutical products that offer a new level of cost effectiveness, improved health and ease of treatment--with an initial focus on the dairy industry. Mach One intends to fully leverage the potential of its breakthrough solutions--breakthroughs that one day will also include consumer applications.

About Modular Process Constructors, LLC

Modular Process Constructors currently designs and builds process equipment used by the biopharmaceutical industry. MPC's skid based solutions offer componentized fabrication for small and large projects reducing lead time, transport cost, and installation time. MPC provides entire project solutions including Documentation, Process Modules, Custom stainless steel fabrication, and Electronic controls to the biopharmaceutical markets.

Cautionary Statement: This news release may include certain "Forward-looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.


'/>"/>
SOURCE Mach One Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):